- Home
- EONR vs NXTC Comparison
EONR vs NXTC Comparison
Compare EONR & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- NXTC
- Stock Information
- Founded
- EONR 2017
- NXTC 2015
- Country
- EONR United States
- NXTC United States
- Employees
- EONR N/A
- NXTC N/A
- Industry
- EONR
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- EONR
- NXTC Health Care
- Exchange
- EONR NYSE
- NXTC Nasdaq
- Market Cap
- EONR 7.8M
- NXTC 9.3M
- IPO Year
- EONR N/A
- NXTC 2019
- Fundamental
- Price
- EONR $0.39
- NXTC $0.41
- Analyst Decision
- EONR Strong Buy
- NXTC Strong Buy
- Analyst Count
- EONR 1
- NXTC 2
- Target Price
- EONR $4.50
- NXTC $3.50
- AVG Volume (30 Days)
- EONR 317.4K
- NXTC 178.3K
- Earning Date
- EONR 05-23-2025
- NXTC 05-01-2025
- Dividend Yield
- EONR N/A
- NXTC N/A
- EPS Growth
- EONR N/A
- NXTC N/A
- EPS
- EONR N/A
- NXTC N/A
- Revenue
- EONR $20,269,293.00
- NXTC N/A
- Revenue This Year
- EONR $46.94
- NXTC N/A
- Revenue Next Year
- EONR $64.38
- NXTC N/A
- P/E Ratio
- EONR N/A
- NXTC N/A
- Revenue Growth
- EONR N/A
- NXTC N/A
- 52 Week Low
- EONR $0.35
- NXTC $0.22
- 52 Week High
- EONR $3.15
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- NXTC 45.41
- Support Level
- EONR N/A
- NXTC $0.34
- Resistance Level
- EONR N/A
- NXTC $0.47
- Average True Range (ATR)
- EONR 0.00
- NXTC 0.06
- MACD
- EONR 0.00
- NXTC 0.01
- Stochastic Oscillator
- EONR 0.00
- NXTC 39.66
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.